Pacira BioSciences, Inc.
PCRX
$25.99
$0.632.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.21% | -9.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.21% | -9.79% | |||
| Cost of Revenue | 18.40% | -42.70% | |||
| Gross Profit | 4.12% | 7.21% | |||
| SG&A Expenses | 2.08% | 9.00% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.75% | 2.14% | |||
| Operating Income | 16.70% | -73.50% | |||
| Income Before Tax | -122.13% | -65.89% | |||
| Income Tax Expenses | -25.01% | -58.95% | |||
| Earnings from Continuing Operations | -200.73% | -70.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -200.73% | -70.00% | |||
| EBIT | 16.70% | -73.50% | |||
| EBITDA | 25.73% | -42.90% | |||
| EPS Basic | -202.50% | -70.06% | |||
| Normalized Basic EPS | -112.78% | -66.10% | |||
| EPS Diluted | -210.00% | -69.82% | |||
| Normalized Diluted EPS | -112.84% | -64.18% | |||
| Average Basic Shares Outstanding | -1.76% | 0.23% | |||
| Average Diluted Shares Outstanding | -2.29% | -5.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||